학술논문
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
Observations and Research
Observations and Research
Document Type
Academic Journal
Author
Perin, Ramir Luan; Magro, Daniela Oliveira; Andrade, Adriana Ribas; Argollo, Marjorie; Carvalho, Nayara Salgado; Damiao, Aderson Omar Moura Cintra; Dotti, Adriana Zanoni; Ferreira, Sandro da Costa; Flores, Cristina; Ludvig, Juliano Coelho; Nones, Rodrigo Bremer; Queiroz, Natalia Sousa Freitas; Parra, Rogerio Serafim; Steinwurz, Flavio; Teixeira, Fabio Vieira; Kotze, Paulo Gustavo
Source
Crohn's & Colitis 360. January 2023, Vol. 5 Issue 1
Subject
Language
English
Abstract
Introduction Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) which affects the colorectal mucosa with a relapsing-remitting pattern that can affect individuals of all ages. The precise etiology [...]
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease which affects the colorectal mucosa with a relapsing-remitting pattern. The therapeutic options currently available for the medical management of UC include many options. Tofacitinib is an oral small molecule, Janus kinase (JAK) inhibitor, more selective for JAK1 and JAK3, which reduces the inflammatory process involved in the pathogenesis of UC. Methods: Retrospective observational multicentric study of patients with UC who used tofacitinib in any phase of their treatment. Clinical remission and response (according to Mayo score), mucosal healing, primary and secondary loss of response, discontinuation of the drug with possible causes, and the need for dose optimization or switching to biologicals, need for surgery and adverse events were evaluated. Results: From a total of 56 included patients, clinical remission was observed in 43.6% at week 12, 54.5% at week 26, 579% at week 52, and 40% at the last follow-up visit. Clinical response was observed in 71.4%, 81.8%, 89.5%, and 61.8% at the same time periods, respectively. Mucosal healing rates were 50% and 178% needed colectomy. Conclusions: Tofacitinib was effective in induction and maintenance of clinical response and remission rates, compatible to other international real-word studies and meta-analyses. Lay Summary The first observational study with tofacitinib in patients with ulcerative colitis from Latin America demonstrated its efficacy and safety, which were compatible to what was described in cohorts from other countries and meta- analyses. Key Words: ulcerative colitis, inflammatory bowel diseases, tofacitinib, Janus kinase inhibitors
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease which affects the colorectal mucosa with a relapsing-remitting pattern. The therapeutic options currently available for the medical management of UC include many options. Tofacitinib is an oral small molecule, Janus kinase (JAK) inhibitor, more selective for JAK1 and JAK3, which reduces the inflammatory process involved in the pathogenesis of UC. Methods: Retrospective observational multicentric study of patients with UC who used tofacitinib in any phase of their treatment. Clinical remission and response (according to Mayo score), mucosal healing, primary and secondary loss of response, discontinuation of the drug with possible causes, and the need for dose optimization or switching to biologicals, need for surgery and adverse events were evaluated. Results: From a total of 56 included patients, clinical remission was observed in 43.6% at week 12, 54.5% at week 26, 579% at week 52, and 40% at the last follow-up visit. Clinical response was observed in 71.4%, 81.8%, 89.5%, and 61.8% at the same time periods, respectively. Mucosal healing rates were 50% and 178% needed colectomy. Conclusions: Tofacitinib was effective in induction and maintenance of clinical response and remission rates, compatible to other international real-word studies and meta-analyses. Lay Summary The first observational study with tofacitinib in patients with ulcerative colitis from Latin America demonstrated its efficacy and safety, which were compatible to what was described in cohorts from other countries and meta- analyses. Key Words: ulcerative colitis, inflammatory bowel diseases, tofacitinib, Janus kinase inhibitors